Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen Completes Acquisition of Novozymes Biopharma Sweden AB
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2012 Results
external link icon
Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results
external link icon
Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
external link icon
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results
external link icon
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia® Lawsuit
corporate icon
Multicomponent Analysis
Challenge: Monitoring multiple analytes simultaneously is difficult with single-channel sensors. Our Solution: Variable pathlength technology supports spectral deconvolution and simultaneous quantification of key analytes.
corporate icon
Hollow Fiber Filters
Ideal for ultrafiltration and microfiltration of shear-sensitive modalities, Spectrum® Hollow Fiber Filters for TFF can accommodate the widest range of scales, membrane chemistries and pore sizes to maximize process outcomes.
external link icon
Repligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance
- Year 2014 Product Sales Increase 27% to a Record $60.4 Million - - Fourth Quarter Product Sales Increase 49% to $15.4 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today reported financial results for the fourth quarter and year ended December 31, 2014. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2015 and access information for today's webcast and conference call. Walter C. Herlihy, Ph.D., President and Chief Executive Officer said, "2014 was an outstanding year for Repligen. We started the year with a focus on accelerating growth and expanding margins in our core business, while investing in our commercial organization and pursuing bioprocessing acquisition opportunities. We executed on all fronts, delivering 27% product sales growth and a 30% increase in gross profit bolstered by our acquisition of the ATF System
external link icon
Repligen Reports Financial Results for the Quarter and Nine-Month Fiscal Year Ended December 31, 2011
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support